Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards. byPallavi MadhirajuDecember 8, 2025